Veklury® (remdesivir)

Covered: a single 3-day course of Veklury (remdesivir) for mild-to-moderate COVID‑19 in adults and pediatric patients ≥28 days old and ≥3 kg who are at high risk for progression to severe disease; excluded are patients <28 days or <3 kg, those not high-risk, SARS‑CoV‑2 negative/untested, repeat/serial courses, or other indications. Key requirements: documented positive SARS‑CoV‑2 test, documentation of age/weight to support weight‑based dosing (≥40 kg: 200 mg Day 1 then 100 mg daily; 3–<40 kg: 5 mg/kg Day 1 then 2.5 mg/kg daily), documentation of high‑risk status, and meeting applicable safety criteria.

"Veklury is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults and pediatric patients (28 days of age and older and weighing at least 3 kg) who has mild-to-moderate COVID-1..."

Sign up to see full coverage criteria, indications, and limitations.